RNAC Q2 2020 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$16M

Net Income

-$24M

EPS (Diluted)

$-7.46

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$75M

Total Liabilities

$88M

Stockholders' Equity

-$13M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$13,000	-100.0%
Gross Profit	$0	$13,000	-100.0%
Operating Income	-$16M	-$16M	-0.8%
Net Income	-$24M	-$16M	-46.9%